CATX — Perspective Therapeutics Share Price
Last trade - 00:00- $671.76m
- $492.83m
- $1.43m
- 58
- 68
- 74
- 74
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.96 | ||
| Price to Tang. Book | 4.36 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | -1,595.89 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -16.46% | ||
| Return on Equity | -22.38% | ||
| Operating Margin | 10190.61% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 7.31 | 9.68 | 10.05 | 10.79 | 1.43 | 0.52 | 0.32 | -24.7% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. It is also developing imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Directors
- Michael Mccormick NEC (58)
- Lori Woods CEO (59)
- Mark Austin CFO (34)
- Jonathan Hunt CFO (54)
- Jennifer Streeter COO (52)
- William Cavanagh OTH (56)
- Alan Hoffmann IND (60)
- Philip Vitale IND (75)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- December 21st, 2018
- Public Since
- May 31st, 2002
- No. of Shareholders
- 243
- No. of Employees
- 116
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 67,378,432
- Address
- 2401 Elliott Avenue, Suite 320, SEATTLE, 98121
- Web
- https://isoray.com/
- Phone
- +1 2066760900
- Auditors
- Assure CPA, LLC
Upcoming Events for CATX
Similar to CATX
Actinium Pharmaceuticals
NYSE MKT
Aeon Biopharma
NYSE MKT
AIM ImmunoTech
NYSE MKT
Armata Pharmaceuticals
NYSE MKT
Azitra
NYSE MKT
FAQ
As of Today at 22:38 UTC, shares in Perspective Therapeutics are trading at $10.09. This share price information is delayed by 15 minutes.
Shares in Perspective Therapeutics last closed at $10.09 and the price had moved by +41.12% over the past 365 days. In terms of relative price strength the Perspective Therapeutics share price has outperformed the S&P500 Index by +12.29% over the past year.
The overall consensus recommendation for Perspective Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Perspective Therapeutics does not currently pay a dividend.
Perspective Therapeutics does not currently pay a dividend.
Perspective Therapeutics does not currently pay a dividend.
To buy shares in Perspective Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $10.09, shares in Perspective Therapeutics had a market capitalisation of $679.85m.
Here are the trading details for Perspective Therapeutics:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: CATX
Based on an overall assessment of its quality, value and momentum Perspective Therapeutics is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Perspective Therapeutics is $22.00. That is 118.04% above the last closing price of $10.09.
Analysts covering Perspective Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.97 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Perspective Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +132.01%.
As of the last closing price of $10.09, shares in Perspective Therapeutics were trading +24.83% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Perspective Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $10.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Perspective Therapeutics' management team is headed by:
- Michael Mccormick - NEC
- Lori Woods - CEO
- Mark Austin - CFO
- Jonathan Hunt - CFO
- Jennifer Streeter - COO
- William Cavanagh - OTH
- Alan Hoffmann - IND
- Philip Vitale - IND